Yes, HRZE can be used in CKD Stage 5, but requires dose and frequency adjustments for pyrazinamide and ethambutol.
In patients with end-stage renal disease (CKD stage 5), the HRZE regimen remains the standard treatment for drug-susceptible tuberculosis, but pyrazinamide and ethambutol must be given three times weekly instead of daily, while isoniazid and rifampin can continue at standard dosing. 1
Specific Dosing Adjustments for CKD Stage 5
Drugs Requiring NO Dose Adjustment:
Isoniazid (H): 300 mg once daily OR 900 mg three times weekly 1
- Metabolized by liver, safe at standard doses
- Add pyridoxine 25-50 mg daily to prevent neuropathy (especially important in renal disease)
Rifampin (R): 600 mg once daily OR 600 mg three times weekly 1
- Hepatically metabolized, not cleared by dialysis
- No adjustment needed
Drugs Requiring Frequency Change:
Pyrazinamide (Z): 25-35 mg/kg three times weekly (NOT daily) 1
- Hepatic metabolism but metabolites (pyrazinoic acid) accumulate in renal failure
- Daily dosing risks toxicity
Ethambutol (E): 20-25 mg/kg three times weekly (NOT daily) 1
- 80% renally cleared, accumulates significantly
- Daily dosing increases risk of optic neuritis
Critical Implementation Details
Timing with dialysis: Administer all medications after hemodialysis on dialysis days to prevent premature drug clearance (particularly pyrazinamide, which is significantly cleared by dialysis) 1. This also facilitates directly observed therapy.
Monitoring requirements:
- Therapeutic drug monitoring should be strongly considered in ESRD patients to ensure adequate absorption without excessive accumulation 1
- Recent evidence shows personalized dosing based on pharmacokinetic profiles enhances efficacy and reduces adverse effects in hemodialysis patients 2
- Monitor for optic neuritis with ethambutol (monthly visual acuity and color vision testing)
- Baseline and periodic renal function assessment, though GFR is already severely compromised
Important Caveats
Immunocompromised status: CKD Stage 5 patients are immunocompromised and have 10-25 times higher TB risk with potentially worse outcomes 2, 3. Close clinical monitoring is essential throughout treatment.
Drug interactions: ESRD patients typically take multiple medications (phosphate binders, immunosuppressants if transplant candidates, etc.) that may interact with anti-TB drugs 1. Rifampin particularly induces cytochrome P450 enzymes.
Treatment duration: Standard 6-month regimen (2HRZE/4HR) applies if using three-times-weekly dosing for pyrazinamide and ethambutol during intensive phase 1. Some experts recommend extending to 9 months in immunocompromised hosts, though this is not universally required.
Peritoneal dialysis: Data are limited; start with hemodialysis dosing recommendations and verify adequacy with therapeutic drug monitoring 1.
Evidence Quality
The dosing recommendations come from the 2016 ATS/CDC/ERS/IDSA guidelines 1, which remain the authoritative source for TB treatment in renal disease. The 2025 guideline update 4 focuses on novel shorter regimens but does not supersede the renal dosing guidance. Recent observational studies 2, 5, 6 support that adjusted regimens are effective and safe, with some evidence that individualized pharmacokinetic-guided dosing further optimizes outcomes.
The key principle: Isoniazid and rifampin maintain standard dosing because they are hepatically metabolized, while pyrazinamide and ethambutol require three-times-weekly (not daily) administration due to renal clearance and metabolite accumulation. This approach balances efficacy against toxicity risk in a vulnerable population.